Bernhoven B.V. — Clinical Trial Site

27 Registered trials

11 Currently recruiting

Organisation

Bernhoven B.V.

Location

Uden, Netherlands

Identifier

ORG-100046245

Address

Nistelrodeseweg 10, 5406 PT, Netherlands

Departments

Cardiology
chirurgie
Department of Gastroenterology & hepatology
Department of Medical Oncology
Ear, nose and throat (ENT) surgery
Gastroenterology
Gastroenterology & Hepatology
Gastroenterology and Hepatology
Hematology
ICU
Internal medicine
Internal medicine / Oncology
Interne Geneeskunde
Medical oncology
Neurology
Oncology
pulmonology
Reumatologie
Urology

Clinical trials at this site (27)

Search interface

A clinical study of MK-7240 for the treatment of ulcerative colitis (MK-7240-001) Unknown

2025-523766-25-00 Ulcerative colitis 5
Adjuvant chemotherapy for prevention of recurrence in patients with detectable ctDNA after surgery in high-riskrectal cancer. Recruiting

2024-517700-12-00 Rectal cancer 5 2025-12-10
A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008) Recruiting

2024-518296-56-00 Crohn’s Disease 5 2025-09-29
REDO-JAK: Dose REDuction Of JAnus Kinase inhibitors in patients with inflammatory rheumatic diseases Recruiting

2025-520757-36-00 Rheumatoid arthritis, psoriatic arthritis and axial spo 6 2025-09-15
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease ( ENHANCE-CD ) Recruiting

2023-508234-34-00 Crohn's disease 4 2025-01-27
Stopping or continuing blood thinners after stroke at young age without a known cause: STOP trial Recruiting

2024-513092-40-00 Stroke 6 2024-12-05
DOSAgE study: A multicenter randomized phase III trial of DOSe-reduced Chemotherapy for Advanced Colorectal Cancer in Older patients Recruiting

2023-506115-17-00 Metastatic Colorectal Cancer 5 2024-10-14
Trastuzumab Deruxtecan (T-DXd) for Subjects with Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC0 Breast Cancer… Recruiting

2023-505616-38-00 Unresectable and/or Metastatic HER2-low or HER2 Immunoh 4 2024-09-04
FeAsiBility of a treatment free interval in newly diagnosed mUltiple myeLOma patients treated with DaratumUmab-Lenalidomide-DexamethaSone – … Recruiting

2023-508586-33-00 multiple myeloma 5 2024-05-14
Staphylococcus aureus Network Adaptive Platform trial (SNAP) Recruiting

2023-503582-35-00 Staphylococcus aureus bacteremia 6 2023-10-26
Renal Lifecycle Trial: A Randomized Controlled Clinical Trial to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in … Recruiting

2023-508389-13-00 Combined endpoint of all-cause mortality, kidney failur 5 2022-11-08
Prevention of opioid-induced constipation in patients with advanced cancer. Recruiting

2023-509462-38-00 Patients with advanced cancer. 11 2022-10-25
A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008) Ended

2023-508636-61-00 Crohn’s Disease 5 2024-10-24
First line treatment with VeNEtoclaX and ibruTinib induction followed by obinutuzumab intenSificaTion Exclusively in CLL/SLL Patients not in… Ended

2022-502808-72-00 Chronic Lymphocytic Leukemia 4 2024-09-11
A Phase 3 Placebo-controlled Study of Milvexian after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack Ended

2022-501176-26-00 Acute Ischemic Stroke and High-Risk Transient Ischemic 5 2023-08-04
A Phase 3, 52-Week, Randomized, Efficacy and Safety Study with Open-Label Extension of BLU-5937 in Adult Participants with Refractory or Une… Ended

2024-513460-26-00 Refractory Chronic Cough, Including Unexplained Chronic 5 2023-03-29
A clinical study to assess the efficacy and safety of lanifibranor followed by an active treatment extension in adult patients with non-cirr… Ended

2023-508248-23-00 Non-alcoholic steatohepatitis (NASH) 5 2021-11-26
Image‐guided de‐escalation of neoadjuvant chemotherapy in HER2‐positive breast cancer: the TRAIN‐3 study Ended

2024-516205-23-00 Breast cancer 4 2019-04-09
Endocrine therapy plus CDK 4/6 inhibition in first- or second-line for hormone receptor positive advanced breast cancer - the SONIA study Ended

2024-516204-42-00 Breast cancer 5 2017-11-21
CRITICS-II Ended

2023-503248-15-00 Patients with TNM 8th ed stage IB-IIC gastric adenocaci 4 2017-10-09
Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) Ended

2023-507889-89-00 Respiratory tract infection 5 2016-02-19
GENPAD Ended

2024-518122-33-00 Peripheral Arterial Disease 6 2024-12-13
ABTECT-1 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -1 Ended

2022-500535-36-01 Moderately to severely active ulcerative colitis 5 2023-06-12
A Study to Evaluate the Efficacy, Safety and Tolerability of a Single Injection of AC102 into the Middle Ear Compared to Oral Steroid Treatm… Ended

2024-513658-31-00 Idiopathic Sudden Sensorineural Hearing Loss 4 2022-08-08